19th Jun 2008 07:00
|
Press Release |
19 June 2008 |
LiDCO Group Plc
("LiDCO" or the "Company")
Update on clinical outcome evidence
LiDCO (AIM:LID), the cardiovascular monitoring company, is pleased to announce that its products have been endorsed in a paper1 presented to the European Society of Anesthesia (ESA) by leading anesthetists from the Charite University Hospital in Berlin.
The authors of this paper were asked to review the guidelines for hemodynamic monitoring in surgery at the annual meeting of the ESA in Copenhagen. They stated about LiDCO's product that "by means of continuously displaying calculated oxygen delivery, goal directed therapy becomes feasible leading to meaningful improvements of outcome in high-risk general surgery patients." During their presentation, the authors further concluded that, using LiDCO technology, "the level of evidence in selected patients reaches [the exacting standard of] 1b" (using the Oxford Centre of Evidence Based Medicine classification of evidence levels2).
Commenting on the results Terry O'Brien, Chief Executive, said: "The LiDCO technology is the only hemodynamic monitoring pressure waveform system to be associated with such a high level of evidence. It has been well documented that its use in surgery patients reduces complications and the costs of care3. The evidence is accumulating for the use of LiDCO's technology in all high-risk surgery patients, which may lead to the eventual adoption of our technology into international anesthetic guidelines. Review articles of this nature underpin our ambitions to take a significant share of the substantial market opportunity for minimally invasive hemodynamic monitoring in both critical care and major surgery patients."
1 Haemodynamic monitoring - update on recent guidelines. Seeling, M., Franck M., Feldheiser, A., Carl M. & Spies, C. Department of anaesthesiology and intensive care medicine, Campus Virchow-Klinikum and Campus Charite Mitte, Berlin, Germany.
2 Oxford Centre of Evidence Based Medicine www.cebm.net/levels_of_evidence.asp
3 Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial. Pearse R., Dawson D., Fawcett J., Rhodes A., Grounds RM., Bennett ED. Crit Care 9 (6) 687-693 (2005).
- ENDS -
For further information, please contact:
|
LiDCO PLC |
|
|
Terry O'Brien (CEO) |
Tel: +44 (0)20 7749 1500 |
|
John Rowland (Company Secretary) |
|
|
Theresa Wallis (Chairman) |
www.lidco.com |
Media enquiries:
|
Abchurch Communications Ltd |
Tel: +44 (0) 20 7398 7710 |
|
Heather Salmond / Stephanie Cuthbert / Simone Alves |
Tel: +44 (0) 20 7398 7718 |
|
www.abchurch-group.com |
Notes to editors
LiDCO (AIM: LID) is a medical technology company that has pioneered minimally invasive technology to monitor and optimize the amount of blood flowing around the body. This ensures that organs and tissues are adequately oxygenated which is crucial in the management of hospital patients requiring risk surgery, critical care or who are at major cardiovascular risk. Clinical studies in patients undergoing high-risk surgery demonstrate that LiDCO's computer-based technology significantly reduces complications and length of stay, saving a hospital as much as £4,800 per patient treated post-operatively and cumulatively up to £2 million pounds a year.
Worldwide there is an increasing demand for minimally invasive hemodynamic monitoring products. LiDCO is targeting a potential US$1.2 billion market opportunity. The Company currently has a worldwide installed base of 1,184 monitors. Income comes from both the sale of monitors and sales of disposable products. The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil, South Korea and Japan. The Company's manufacturing facility is in Hoxton, UK. It sells direct in the UK and USA, and elsewhere through a worldwide network of speciality critical care and anesthesia distributors.
LiDCO's technology was developed by United Dental and Medical Schools of St Thomas' and Guys Hospitals (now King's College London) and is endorsed and used by major teaching hospitals in the EU, UK and USA.
Products
* LiDCOplus and PulseCO monitors: computer-based platforms that are used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid volume status
* LiDCOrapid: A new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management at the point of care
* LiDCO disposables: lithium sensor kit used in conjunction with the LiDCOplus Monitor for accurate measurement of cardiac output in a minimally invasive manner and the LiDCOsmart card used in conjunction with the LiDCOrapid Monitor.
* LiDCOview: an easy-to-use graphical display of historical LiDCOplus hemodynamic data. Both clinical researchers and routine users can view beat-to-beat hemodynamic data collected with the LiDCOplus. LiDCOviewSE is the standard version of this tool and is available for free, allowing anyone to download and access data from the LiDCOplus. LiDCOviewPRO is the Professional version, allowing users to analyse, export and report the LiDCOplus data. A free trial of LiDCOviewPRO is available for evaluation purposes prior to purchase
* LiDCOlive: a software product in development for the remote display of hemodynamic monitoring parameters derived through use of the LiDCOplus or LiDCOrapid monitors
Related Shares:
LID.L